Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.55 | N/A | +21.60% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.55 | N/A | +21.60% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management highlighted the strong EPS performance but did not offer detailed insights into revenue. They remain focused on future growth opportunities.
Management did not provide specific revenue figures for the quarter.
They expressed confidence in their product pipeline.
United Therapeutics reported a strong EPS, exceeding expectations, but the stock fell by over 5% in reaction. Investors may be concerned about the lack of revenue details and future guidance, which could indicate uncertainty about the company's performance going forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE CONNECTIONS IN
Apr 27, 2015